Newsfeeds - Spark Newswire

1 minute read

Inhibrx Says Based On FDA Discussions, There Is Potential To Pursue Accelerated Approval For INBRX-101

Today, 2:41 AM

SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on

INBX

6 minute read

Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday

By Lisa Levin

Today, 2:41 AM

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.

ABVC

4 minute read

Recap Of Monday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 2:41 AM

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…

ANIX

1 minute read

Inhibrx Announces European Medicines Agency Grants Orphan Drug Designation To INBRX-109 For The Treatment Of Chondrosarcoma

By Benzinga Newsdesk

Today, 2:41 AM

Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the European Commission ("EC"), based on a positive opinion

INBX

5 minute read

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday

By Lisa Levin

Today, 2:41 AM

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

AEG

24 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 2:41 AM

On Friday, 422 stocks made new 52-week lows.

AAT

6 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 2:41 AM

During the Thursday's session, 100 stocks hit new 52-week lows.

ACOR

5 minute read

73 Biggest Movers From Yesterday

By Lisa Levin

Today, 2:41 AM

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.

ACLX

1 minute read

Inhibrx’s INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

By Vandana Singh

Today, 2:41 AM

Inhibrx Inc (NASDAQ:INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein,…

INBX

3 minute read

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More

By Shanthi Rexaline

Today, 2:41 AM

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.

ATNX